Intergroupe Francophone Du Myelome
Clinical trials sponsored by Intergroupe Francophone Du Myelome, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug teclistamab tested in patients with Hard-to-Treat myeloma Results expected Dec 2026 (estimated)
-
New drug teclistamab tested in patients with Hard-to-Treat myeloma
Disease control OngoingThis study is tracking 200 adults with multiple myeloma whose cancer has returned or stopped responding to treatment. They are receiving teclistamab, a drug that helps the immune system find and destroy myeloma cells. Researchers are measuring how many patients respond to the dru…
Sponsor: Intergroupe Francophone du Myelome • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Pee break: spot urine test could end 24-Hour jug hassle for myeloma patients
Diagnosis OngoingThis study tests whether a single urine sample (spot urine) can detect myeloma proteins as accurately as the standard 24-hour urine collection. Researchers will compare results from 180 multiple myeloma patients starting a new treatment. If the spot test works well, it could make…
Sponsor: Intergroupe Francophone du Myelome • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC